BG
CTIC

BlackRock Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

BlackRock Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,991
Closed -$26K – 3107
2016
Q1 		$26K Buy
4,991
+3,661
+275% +$29.3K ﹤0.01% 3011
2015
Q4 		$16K Hold
1,330
– – ﹤0.01% 2966
2015
Q3 		$19K Buy
+1,330
New +$23K ﹤0.01% 2990

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock Group's CTIC Position: Q2 2016 in Review

BlackRock Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2016, closing a stake of 4,991 shares — an estimated $26K sold.

BlackRock Group first reported a position in CTIC in Q3 2015 and held it in 3 quarters. The position peaked at $26K in Q1 2016. 67 funds tracked by Wall St. Rank hold CTIC as of Q2 2016.

  • BlackRock Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 4,991 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2016, an estimated $26K.
  • BlackRock Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2015 and held it in 3 quarters.
  • BlackRock Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $26K in Q1 2016.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.